Chemical Compound Review:
Tomudex (2S)-2-[[5-[methyl-[(2- methyl-4-oxo-1H...
Synonyms:
Raltitrexed, SureCN7438, SureCN7439, ZD-16, ICI-D-1694, ...
Fizazi,
Doubre,
Le Chevalier,
Riviere,
Viala,
Daniel,
Robert,
Barthélemy,
Fandi,
Ruffié,
Scheithauer,
Kornek,
Schuell,
Ulrich-Pur,
Penz,
Raderer,
Lang,
Schneeweiss,
Lenauer,
Depisch,
Peters,
Smitskamp-Wilms,
Smid,
Pinedo,
Jansen,
van Meerbeeck,
Gaafar,
Manegold,
Van Klaveren,
Van Marck,
Vincent,
Legrand,
Bottomley,
Debruyne,
Giaccone,
- Raltitrexed, a new drug for advanced colorectal cancer. Mead, G.M. Lancet (1996)
- Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Maughan, T.S., James, R.D., Kerr, D.J., Ledermann, J.A., McArdle, C., Seymour, M.T., Cohen, D., Hopwood, P., Johnston, C., Stephens, R.J. Lancet (2002)
- Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Longo, G.S., Gorlick, R., Tong, W.P., Ercikan, E., Bertino, J.R. Blood (1997)
- Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. Fizazi, K., Doubre, H., Le Chevalier, T., Riviere, A., Viala, J., Daniel, C., Robert, L., Barthélemy, P., Fandi, A., Ruffié, P. J. Clin. Oncol. (2003)
- Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Peters, G.J., Smitskamp-Wilms, E., Smid, K., Pinedo, H.M., Jansen, G. Cancer Res. (1999)
- The costs of managing advanced colorectal cancer: a broad perspective. Kerr, D.J., O'Connor, K.M. Anticancer Drugs (1997)
- Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability. Thomas, R.J., Williams, M., Garcia-Vargas, J. Clinical oncology (Royal College of Radiologists (Great Britain)) (2003)
- Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. Johnston, P.G., Behan, K.A., Allegra, C.J., Drake, J.C. J. Natl. Cancer Inst. (1995)
- The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Wielinga, P., Hooijberg, J.H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., van der Born, K., de Haas, M., van der Heijden, I., Kaspers, G., Wijnholds, J., Jansen, G., Peters, G., Borst, P. Cancer Res. (2005)
- Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. McDermott, U., Longley, D.B., Galligan, L., Allen, W., Wilson, T., Johnston, P.G. Cancer Res. (2005)
- A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes. Liao, Z.Y., Sordet, O., Zhang, H.L., Kohlhagen, G., Antony, S., Gmeiner, W.H., Pommier, Y. Cancer Res. (2005)
- Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. van Meerbeeck, J.P., Gaafar, R., Manegold, C., Van Klaveren, R.J., Van Marck, E.A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., Giaccone, G. J. Clin. Oncol. (2005)
- Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. Rustum, Y.M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M.B., Wilke, H., Seeber, S. J. Clin. Oncol. (1997)
- Thymidylate synthase inhibitors. Touroutoglou, N., Pazdur, R. Clin. Cancer Res. (1996)
- Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. van Triest, B., Pinedo, H.M., van Hensbergen, Y., Smid, K., Telleman, F., Schoenmakers, P.S., van der Wilt, C.L., van Laar, J.A., Noordhuis, P., Jansen, G., Peters, G.J. Clin. Cancer Res. (1999)
- Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Scheithauer, W., Kornek, G.V., Schuell, B., Ulrich-Pur, H., Penz, M., Raderer, M., Lang, F., Schneeweiss, B., Lenauer, A., Depisch, D. Ann. Oncol. (2001)
- Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. Porta, C. Cancer Treat. Rev. (2006)
- Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Li, W.W., Fan, J., Hochhauser, D., Bertino, J.R. Cancer Res. (1997)
- ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Jackman, A.L., Taylor, G.A., Gibson, W., Kimbell, R., Brown, M., Calvert, A.H., Judson, I.R., Hughes, L.R. Cancer Res. (1991)
- DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Matsui, S.I., Arredondo, M.A., Wrzosek, C., Rustum, Y.M. Cancer Res. (1996)
- Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Maxwell, P.J., Longley, D.B., Latif, T., Boyer, J., Allen, W., Lynch, M., McDermott, U., Harkin, D.P., Allegra, C.J., Johnston, P.G. Cancer Res. (2003)
- The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. Keyomarsi, K., Samet, J., Molnar, G., Pardee, A.B. J. Biol. Chem. (1993)
- Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells. Shaw, D., Berger, F.G., Spencer, H.T. Hum. Gene Ther. (2001)
- Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. Clarke, S.J., Hanwell, J., de Boer, M., Planting, A., Verweij, J., Walker, M., Smith, R., Jackman, A.L., Hughes, L.R., Harrap, K.R., Kennealey, G.T., Judson, I.R. J. Clin. Oncol. (1996)
- A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Wang, Y., Zhao, R., Chattopadhyay, S., Goldman, I.D. Cancer Res. (2002)
- Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. Popescu, R.A., Norman, A., Ross, P.J., Parikh, B., Cunningham, D. J. Clin. Oncol. (1999)
- Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro. Patterson, A.V., Talbot, D.C., Stratford, I.J., Harris, A.L. Cancer Res. (1998)
- Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. Yin, M.B., Guo, B., Panadero, A., Frank, C., Wrzosek, C., Slocum, H.K., Rustum, Y.M. Exp. Cell Res. (1999)
- p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Yin, M.B., Voigt, W., Panadero, A., Vanhoefer, U., Frank, C., Pajovic, S., Azizkhan, J., Rustum, Y.M. Mol. Pharmacol. (1997)
- Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Jackman, A.L., Boyle, F.T., Harrap, K.R. Investigational new drugs. (1996)
- Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Maughan, T.S., James, R.D., Kerr, D.J., Ledermann, J.A., Seymour, M.T., Topham, C., McArdle, C., Cain, D., Stephens, R.J. Lancet (2003)
- Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Smith, S.G., Lehman, N.L., Moran, R.G. Cancer Res. (1993)
- ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. Zalcberg, J.R., Cunningham, D., Van Cutsem, E., Francois, E., Schornagel, J., Adenis, A., Green, M., Iveson, A., Azab, M., Seymour, I. J. Clin. Oncol. (1996)